152 related articles for article (PubMed ID: 821321)
1. Role of manganese in dystonia.
Barbeau A; Inoué N; Cloutier T
Adv Neurol; 1976; 14():339-52. PubMed ID: 821321
[TBL] [Abstract][Full Text] [Related]
2. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
Marsden CD
Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927
[No Abstract] [Full Text] [Related]
3. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias).
Barbeau A
Neurotoxicology; 1984; 5(1):13-35. PubMed ID: 6538948
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis of manganese-induced parkinsonism.
Cersosimo MG; Koller WC
Neurotoxicology; 2006 May; 27(3):340-6. PubMed ID: 16325915
[TBL] [Abstract][Full Text] [Related]
5. The pharmacology of extrapyramidal movement disorders.
Klawans HL
Monogr Neural Sci; 1973; 2():1-136. PubMed ID: 4271860
[No Abstract] [Full Text] [Related]
6. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.
Lees AJ; Shaw KM; Stern GM
Lancet; 1977 Nov; 2(8046):1034. PubMed ID: 72935
[No Abstract] [Full Text] [Related]
7. Rationale for the use of L-dopa in the torsion dystonias.
Barbeau A
Neurology; 1970 Nov; 20(11):96-102. PubMed ID: 4991253
[No Abstract] [Full Text] [Related]
8. Manganese neurotoxicity: a review of clinical features, imaging and pathology.
Pal PK; Samii A; Calne DB
Neurotoxicology; 1999; 20(2-3):227-38. PubMed ID: 10385886
[TBL] [Abstract][Full Text] [Related]
9. Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia.
Lindvall B; Olsson JE
Adv Neurol; 1990; 53():117-22. PubMed ID: 1700581
[No Abstract] [Full Text] [Related]
10. [Case report. Dystonia musculorum deformans after carbon monoxide poisoning (author's transl)].
Franke A; Neu I
Nervenarzt; 1977 Jun; 48(6):345-7. PubMed ID: 895957
[No Abstract] [Full Text] [Related]
11. [Neurologic and psychic complications in treatment with neuroleptics].
Gerlach J
Ugeskr Laeger; 1976 Jun; 138(27):1650-3. PubMed ID: 951778
[No Abstract] [Full Text] [Related]
12. Involuntary movement disorders.
Still CN
Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
[TBL] [Abstract][Full Text] [Related]
13. [Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
Destee A
LARC Med; 1984 Feb; 4(2):107-11. PubMed ID: 6232436
[No Abstract] [Full Text] [Related]
14. Catecholamines and neurologic diseases (second of two parts).
Moskowitz MA; Wurtman RJ
N Engl J Med; 1975 Aug; 293(7):332-8. PubMed ID: 125386
[No Abstract] [Full Text] [Related]
15. [Microelement metabolism in patients with hereditary extrapyramidal diseases].
Borisova TV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1978; 78(2):217-21. PubMed ID: 147595
[TBL] [Abstract][Full Text] [Related]
16. [Deep brain stimulation for Parkinson's disease and dystonia].
Yokochi F
Brain Nerve; 2009 Apr; 61(4):473-83. PubMed ID: 19378817
[TBL] [Abstract][Full Text] [Related]
17. Biochemical evidence for brain neurotransmitter changes in idiopathic torsion dystonia (dystonia musculorum deformans).
Hornykiewicz O; Kish SJ; Becker LE; Farley I; Shannak K
Adv Neurol; 1988; 50():157-65. PubMed ID: 2456673
[No Abstract] [Full Text] [Related]
18. Searching for a relationship between manganese and welding and Parkinson's disease.
Jankovic J
Neurology; 2005 Jun; 64(12):2021-8. PubMed ID: 15985567
[TBL] [Abstract][Full Text] [Related]
19. Network biomarkers for the diagnosis and treatment of movement disorders.
Poston KL; Eidelberg D
Neurobiol Dis; 2009 Aug; 35(2):141-7. PubMed ID: 19013242
[TBL] [Abstract][Full Text] [Related]
20. [Occupational neurotoxicology due to heavy metals-especially manganese poisoning].
Inoue N
Brain Nerve; 2007 Jun; 59(6):581-9. PubMed ID: 17585589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
